| scholarly article | Q13442814 |
| P2093 | author name string | Gary C Curhan | |
| Chi-yuan Hsu | |||
| Charles E McCulloch | |||
| P433 | issue | 2 | |
| P921 | main subject | epidemiology | Q133805 |
| P304 | page(s) | 504-510 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey | |
| P478 | volume | 13 |
| Q35105827 | A 3-marker index improves the identification of iron disorders in CKD anaemia. |
| Q47685491 | A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE. |
| Q46035631 | Altered brain functional connectivity in hemodialysis patients with end-stage renal disease: a resting-state functional MR imaging study. |
| Q44503716 | Anaemia in diabetic patients with chronic kidney disease--prevalence and predictors |
| Q33412594 | Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study |
| Q33719996 | Anemia and chronic kidney disease are potential risk factors for mortality in stroke patients: a historic cohort study |
| Q35907946 | Anemia and risk for cognitive decline in chronic kidney disease |
| Q33899258 | Anemia is independently associated with NT-proBNP levels in asymptomatic predialysis patients with chronic kidney disease |
| Q55431731 | Anemia modifies the prognostic value of glycated hemoglobin in patients with diabetic chronic kidney disease. |
| Q36547312 | Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists |
| Q89522819 | Application of Reticulocyte-Based Estimation of Red Blood Cell Lifespan in Anemia Management of End-Stage Renal Disease Patients |
| Q47441195 | Association of adiposity with hemoglobin levels in patients with chronic kidney disease not on dialysis |
| Q36745330 | Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health care |
| Q36509994 | Blood lipids, infection, and inflammatory markers in the Tsimane of Bolivia |
| Q36666810 | C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. |
| Q35538153 | Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors |
| Q37162982 | Characteristics of the small bowel lesions detected by capsule endoscopy in patients with chronic kidney disease |
| Q56761591 | Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients |
| Q48727034 | Content validation of two SF-36 subscales for use in type 2 diabetes and non-dialysis chronic kidney disease-related anemia. |
| Q38637669 | Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. |
| Q34751907 | Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial |
| Q37073952 | Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: A nested case-control study |
| Q35672484 | Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease |
| Q89642087 | Does contrast media volume affect long-term survival in patients with chronic kidney disease? |
| Q46059118 | Does posttransplant anemia at 6 months affect long-term outcome of live-donor kidney transplantation? A single-center experience |
| Q90594296 | Effects of Molidustat in the Treatment of Anemia in CKD |
| Q46248791 | Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice |
| Q90209853 | Effects of erythropoietin on fibroblast growth factor 23 in mice and humans |
| Q33992079 | Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol |
| Q37119904 | Elevated galectin-3 precedes the development of CKD |
| Q36948689 | Epidemiology of anemia in older adults |
| Q36461581 | Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease |
| Q45109843 | Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow |
| Q35758271 | Estimated GFR, albuminuria, and complications of chronic kidney disease |
| Q64271549 | Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa |
| Q33854988 | Extended dosing of darbepoetin alfa in peritoneal dialysis patients |
| Q34628344 | Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial |
| Q39611816 | High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults |
| Q41189183 | Hospital-acquired acute kidney injury: an analysis of baseline estimated glomerular filtration rate and in-hospital mortality |
| Q36163475 | Impact of anaemia on lung function and exercise capacity in patients with stable severe chronic obstructive pulmonary disease |
| Q37108314 | Impact of low hemoglobin on the development of contrast-induced nephropathy: A retrospective cohort study |
| Q36345724 | Impacts of anemia on 3-year ischemic events in patients undergoing percutaneous coronary intervention: a propensity-matched study |
| Q42361985 | Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model |
| Q33801065 | Interpretation of Erythropoietin and Haemoglobin Levels in Patients with Various Stages of Chronic Kidney Disease |
| Q37042142 | Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. |
| Q37002467 | Left ventricular hypertrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: the multi-ethnic study of atherosclerosis (MESA) |
| Q35294769 | Lower gastrointestinal bleeding in chronic hemodialysis patients |
| Q35000389 | Lower urinary connective tissue growth factor levels and incident CKD stage 3 in the general population |
| Q35272304 | Measured GFR does not outperform estimated GFR in predicting CKD-related complications |
| Q34047965 | Modeling red blood cell survival data |
| Q92774621 | Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies |
| Q36162241 | Parathyroid hormone may be an early predictor of low serum hemoglobin concentration in patients with not advanced stages of chronic kidney disease. |
| Q35624242 | Performance of a genetic risk score for CKD stage 3 in the general population |
| Q58696069 | Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis |
| Q35811858 | Predictors of anemia in a multi-ethnic chronic kidney disease population: a case-control study |
| Q34405409 | Prevalence of CKD in northeastern Italy: results of the INCIPE study and comparison with NHANES. |
| Q45969386 | Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. |
| Q35083495 | Prevalence of anemia in chronic kidney disease in the United States |
| Q49195291 | Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study |
| Q50442683 | Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). |
| Q92889691 | Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF |
| Q37337424 | Relation of hemoglobin to level of cognitive function in older persons |
| Q37090801 | Relationship between silent brain infarction and chronic kidney disease |
| Q35115561 | Renal anemia: a nephrologist's view. |
| Q54200340 | Renal functional outcomes after surgery for renal cortical tumors. |
| Q51552133 | Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. |
| Q37090501 | SOD2 deficiency in hematopoietic cells in mice results in reduced red blood cell deformability and increased heme degradation |
| Q47114967 | Safety and efficacy of ferric citrate in phosphate reduction and iron supplementation in patients with chronic kidney disease |
| Q49791535 | Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis |
| Q36738420 | Selected physiologic variables are weakly to moderately associated with 29 biomarkers of diet and nutrition, NHANES 2003-2006. |
| Q35218230 | Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease |
| Q47558235 | Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. |
| Q39032621 | Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. |
| Q47102803 | Special issue: iron therapy in patients with chronic kidney disease. |
| Q33380999 | Splenomegaly, hypersplenism and peripheral blood cytopaenias in patients with classical Anderson-Fabry disease |
| Q37039758 | The Association between Parathyroid Hormone Levels and Hemoglobin in Diabetic and Nondiabetic Participants in the National Kidney Foundation's Kidney Early Evaluation Program. |
| Q36333126 | The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale |
| Q92921916 | The Influence of Inflammation on Anemia in CKD Patients |
| Q58914650 | The effect of admission creatinine levels on one-year mortality in acute myocardial infarction |
| Q57463191 | The influence of chronic kidney disease on the duration of hospitalisation and transfusion rate after elective hip and knee arthroplasty |
| Q37170058 | The risk of acute renal failure in patients with chronic kidney disease |
| Q37042178 | Timing of onset of CKD-related metabolic complications |
| Q36285948 | Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations |
| Q34857944 | Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). |
| Q34073285 | Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1. |
| Q82520568 | [Renal anemia - an important secondary disease in renal insufficiency] |
Search more.